Related Experiment Video

Updated: Mar 7, 2026

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.6K

Non-coding RNAs in cardiac hypertrophy

Lara Ottaviani1, Paula A da Costa Martins1,2

  • 1Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.

The Journal of Physiology
|February 25, 2017
PubMed

Insights

Non-coding RNAs are key regulators of heart function. Their dysregulation contributes to heart failure, offering potential as new diagnostic markers and therapeutic targets for improved patient outcomes.

Area of Science:

  • Cardiovascular Biology
  • Molecular Genetics
  • Genomics

Background:

  • Heart failure presents a significant global health challenge with poor prognosis despite advances.
  • Current treatments are limited, with heart transplantation being the only cure.
  • Understanding molecular pathways is crucial for identifying new therapeutic targets.

Purpose of the Study:

  • To review recent discoveries on non-coding RNAs in cardiac hypertrophy and heart failure.
  • To explore the role of non-coding RNAs in the pathophysiology of heart disease.
  • To highlight non-coding RNAs as potential diagnostic/prognostic biomarkers and therapeutic targets.

Main Methods:

  • Literature review of recent research on non-coding RNAs and cardiac disease.
  • Analysis of molecular pathways and interactions involving non-coding RNAs.
  • Synthesis of pre-clinical findings on non-coding RNA therapeutics and biomarkers.

Main Results:

  • Non-coding RNAs are fundamental regulators of cellular functions.
  • Dysregulation of non-coding RNAs is increasingly linked to cardiac pathology.
  • Pre-clinical studies show non-coding RNAs as valuable therapeutic targets and biomarkers for heart failure.

Conclusions:

  • Non-coding RNAs play a critical role in the progression of cardiac hypertrophy and heart failure.
  • Non-coding RNA-based strategies hold promise for future clinical applications in heart failure treatment.
  • Further research is expected to translate these findings into effective bedside therapies.

Keywords:
heart failurehypertrophyintracellular communicationnon-coding RNA

More Related Videos

Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts09:29

Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts

Published on: March 22, 2017

7.9K
Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

25.7K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
588
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
688
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
722